Extended follow ‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial)

British Journal of Haematology, EarlyView.

Source: British Journal of Haematology - August 20, 2018 Category: Hematology Authors: Rakesh Popat , Sarah R. Brown , Louise Flanagan , Andrew Hall , Walter Gregory , Bhuvan Kishore , Matthew Streetly , Heather Oakervee , Kwee Yong , Gordon Cook , Eric Low , Jamie Cavenagh , on behalf of Source Type: research